The_DT
effect_NN
of_IN
toremifene_NN
therapy_NN
on_IN
serum_NN
immunoglobulin_NN
levels_NNS
in_IN
breast_NN
cancer_NN
._.

Estrogens_NNS
and_CC
anti-estrogens_NNS
enhance_VBP
the_DT
number_NN
of_IN
immunoglobulin_NN
-LRB-_-LRB-
Ig_NN
-RRB-_-RRB-
-_:
secreting_NN
cells_NNS
in_IN
pokeweed_NN
mitogen_NN
-LRB-_-LRB-
PWM_NN
-RRB-_-RRB-
-_:
stimulated_JJ
lymphocyte_NN
cultures_NNS
._.

Lymphocytes_NNS
from_IN
patients_NNS
who_WP
have_VBP
received_VBN
anti-estrogen_JJ
therapy_NN
show_VBP
similar_JJ
enhancement_NN
of_IN
Ig-secreting_JJ
cells_NNS
after_IN
PWM_NN
stimulation_NN
._.

In_IN
this_DT
study_NN
the_DT
effect_NN
of_IN
anti-estrogen_NN
-LRB-_-LRB-
toremifene_NN
-RRB-_-RRB-
therapy_NN
on_IN
serum_NN
immunoglobulin_NN
-LRB-_-LRB-
IgA_NN
,_,
IgM_NN
,_,
IgG_NN
-RRB-_-RRB-
levels_NNS
in_IN
breast_NN
cancer_NN
patients_NNS
was_VBD
investigated_VBN
._.

Serum_NN
Ig_NN
levels_NNS
were_VBD
followed_VBN
up_RB
to_TO
two_CD
years_NNS
after_IN
or_CC
during_IN
the_DT
therapy_NN
._.

An_DT
unexpected_JJ
finding_NN
was_VBD
that_IN
the_DT
Ig_NN
levels_NNS
decreased_VBD
during_IN
the_DT
follow-up_JJ
period_NN
._.

This_DT
decrease_NN
was_VBD
seen_VBN
in_IN
patients_NNS
who_WP
responded_VBD
to_TO
the_DT
therapy_NN
as_RB
well_RB
as_IN
in_IN
those_DT
who_WP
did_VBD
not_RB
._.

